Savant Capital LLC Invests $220,000 in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Savant Capital LLC purchased a new stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 13,950 shares of the company’s stock, valued at approximately $220,000.

A number of other institutional investors have also added to or reduced their stakes in RDY. Robeco Institutional Asset Management B.V. grew its stake in shares of Dr. Reddy’s Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after buying an additional 9,373,412 shares during the last quarter. Artemis Investment Management LLP boosted its holdings in shares of Dr. Reddy’s Laboratories by 398.3% during the 4th quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock valued at $4,666,000 after acquiring an additional 236,224 shares in the last quarter. Fisher Asset Management LLC grew its position in Dr. Reddy’s Laboratories by 59.4% during the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock worth $39,034,000 after acquiring an additional 183,146 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Dr. Reddy’s Laboratories by 219.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 155,481 shares of the company’s stock worth $12,353,000 after purchasing an additional 106,796 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in Dr. Reddy’s Laboratories by 441.8% in the fourth quarter. Nordea Investment Management AB now owns 125,363 shares of the company’s stock valued at $1,992,000 after purchasing an additional 102,226 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Stock Performance

NYSE:RDY opened at $13.57 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $13.36 and a fifty-two week high of $16.89. The company has a 50 day simple moving average of $14.71 and a two-hundred day simple moving average of $15.26. The company has a market capitalization of $11.32 billion, a PE ratio of 21.60 and a beta of 0.50.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Analysts Set New Price Targets

RDY has been the subject of a number of research reports. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. Barclays cut their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Finally, StockNews.com downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.